Westlake BioPartners Opportunity Fund I, L.P. bought $1000K of Kyverna Therapeutics (KYTX)

Executed Dec 18 2025, disclosed Dec 22 2025, 4 days later.

Value, as filed

$1000K

133,333 sh × $7.50

Executed

Dec 18 2025

the trade date, as filed

Disclosed

Dec 22 2025

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+44.4%

+27.4% from execution

Over the 21 trading sessions from the disclosed entry session (Dec 22 2025), the stock returned +44.4% (delay-adjusted); from the execution session (Dec 18 2025), +27.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

WP Westlake BioPartners Opportunity Fund I, L.P. 10% owner profile →

Westlake BioPartners Opportunity Fund I, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in KYTX. Across 1 priced purchase filing, the average 21-session return was +27.4% from execution and +44.4% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of KYTX (133,333 sh × $7.50, as filed), executed Dec 18 2025.

The name

KYTX KYTX KYTX · 3 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→